The global musculoskeletal oncology therapeutics market size is projected to be worth US$ 1,805 Mn in 2022. During the projection period of 2022 to 2032, the market is predicted to grow at a CAGR of 4.5%, with a valuation of US$ 2,803.11 Mn by 2032. Some of the factors influencing the demand for musculoskeletal oncology therapeutics include:
Musculoskeletal oncology, also referred to as orthopedic oncology, is a highly specialised branch of orthopedic surgery. Musculoskeletal oncology is used in the treatment of sculoskeletal cancers and tumours.
Bone and soft tissue tumors are quite rare and sometimes require reconstructive surgery. Soft tissue sarcomas are more common than bone sarcomas. For 2016, the American Cancer Society estimates about 3,300 new cases for cancer of the bones and joints,and 12,310 new cases for soft tissue sarcomas.
| Attributes | Details |
|---|---|
| Musculoskeletal Oncology Therapeutics Market Value (2022) | US$ 1,805 Million |
| Musculoskeletal Oncology Therapeutics Market Forecast Value (2032) | US$ 2,803.11 Million |
| Musculoskeletal Oncology Therapeutics Market CAGR (2022 to 2032) | 4.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Chondrosarcoma is more prevalent than other form of cancers and swift diagnosis and effective treatment remains a challenge for healthcare providers. Treatment with chemotherapy and radiotherapy do not remain the preferred choice of treatment in treating such type of tumor as clinical studies demonstrate no substantial improvements in the survival rate of the patients.
Therefore, adequate surgical resection is the mainstay of treatment in case of chondrosarcoma. As estimated by the American Cancer Society, chondrosarcomas is more prevalent with 40% of cases developing in adults whereas less than 5% of cases occur in patients who are less than 20 years old.
Radiofrequency ablation has become the standard and most preferred choice of treatment in case of osteoid osteoma, a benign bone tumor that arises from osteoblasts. However, studies demonstrates its expanded application in palliative treatment of patients with painful bone metastasis.
The ability to perform less invasive procedures often allows more efficient, less painful, and more cost-effective patient care. In addition, minimally invasive techniques, such as kyphoplasty, vertebroplasty, and acetabuloplasty may provide an alternative to major reconstructive surgery for patients with metastatic disease.
One of the prime factors driving the global musculoskeletal oncology therapeutics market includes rapidly ageing population with increasing risk of developing cancer. Patients who had prior high-dose external radiation therapy or treatment with anti-cancer drugs are at higher risk of developing osteosarcoma.
However, a small number of bone cancers also develop due to heredity defects of bones; people with metal implants, which doctors sometimes use to repair fractures, are more likely to develop osteosarcoma. In case of soft tissue sarcoma, adults with heredity disorders such as retinoblastoma, tuberous sclerosis, and Werner syndrome are at a higher risk of developing this type of cancer.
Development of safe and effective treatment procedures has also bolstered the growth of the musculoskeletal oncology therapeutics market. For example, image-guided surgery systems, primarily used in joints reconstruction, have been applied to orthopedic oncology.
This may prove beneficial for areas such as the pelvis, where the complex anatomy makes the functional result difficult to interpret. Also, increasing focus of orthopedic oncologists to integrate advances in the surgical techniques by collaboration with subspecialties is also expected to boost the growth of the market during the forecast period, 2016-2026.
Unwanted complications associated with the radiation therapy, such as increased risk of wound complications and of post radiation fractures is hampering the musculoskeletal oncology therapeutics market growth. Additionally, high cost associated with the treatment and lack of awareness regarding the effective treatment therapies can also pose challenges to adoption during the forecast period.
Principal Consultant
In the past few years, significant advancements have been made in treatment of musculoskeletal oncology related disorders. Yet, there is an urgent need to develop more sophisticated and highly advanced techniques to best manage hard-to-treat osteosarcomas.
Rising prevalence of musculoskeletal disorders is expected to increase emphasis on developing effective treatment procedures for cancers related to bones and soft tissues. Owing to these factors, the musculoskeletal oncology therapeutics market is expected to expand at a healthy growth rate during the forecast period.
On the basis of region presence, musculoskeletal oncology therapeuticsmarket is segmented into seven key regions: North America, Latin America, and Eastern Europe, Western Europe, and Asia pacific excluding Japan (APEJ), Japan, Middle East and Africa.
Europe and North America are the largest markets for musculoskeletal oncology therapeutics, owing to increased R&D investments and high level of awareness among end-users. Asia pacific represents immense growth opportunity for musculoskeletal oncology therapeutics market, owing to high population and increase in the prevalence of cancer.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key market players in the musculoskeletal oncology therapeutics market are Stryker Corporation, Accentus Inc., Roche Diagnostics, Amgen Inc., Novartis AG, Biogen dec, GlaxoSmithKline, Sanofi S.A., and Pfizer Inc.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Musculoskeletal oncology therapeutics marketis segmented on the basis of diagnosis, treatment, end-user, and geography.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Diagnosis 6.2. Treatment 7. Global Market Analysis and Forecast, By Diagnosis 7.1. X-Ray 7.2. Magnetic Resonance Imaging (MRI) Scan 7.3. Computed Tomography (CT) Scan 7.4. Positron Emission Tomography (PET) Scan 7.5. Biopsy 8. Global Market Analysis and Forecast, By Treatment 8.1. Surgery 8.2. Amputation 8.3. Limb Salvage Surgery 8.4. Reconstructive Surgery 8.5. Chemotherapy 8.6. Radiation Therapy 8.7. Immunotherapy 8.8. Targeted Therapy 9. Global Market Analysis and Forecast, By Region 9.1. Multispecialty Hospitals 9.2. Cancer Research Institutes 9.3. Diagnostic Centers 10. Multispecialty Hospitals Sales Analysis and Forecast, by Key Segments and Countries 11. Cancer Research Institutes Sales Analysis and Forecast, by Key Segments and Countries 12. Diagnostic Centers Sales Analysis and Forecast, by Key Segments and Countries 13. Sales Forecast by Diagnosis and Treatment for 30 Countries 14. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 15. Company Profile 15.1. Stryker Corporation 15.2. Accentus Inc. 15.3. Roche Diagnostics 15.4. Amgen Inc. 15.5. Novartis AG 15.6. Biogen Inc. 15.7. GlaxoSmithKline 15.8. Sanofi S.A. 15.9. Pfizer Inc.
Explore Healthcare Insights
View Reports
Musculoskeletal Oncology Therapeutics Market
